The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...

The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...

Gilead is a dominant player in the HIV market. Biktarvy is the number one prescribed regimen for both treatment-naïve and switch patients. It continues to maintain its dominant position with an ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

Early diagnosis is vital for HIV. The sooner you receive a blood test and diagnosis, the sooner you can start treatment to bring and keep HIV at undetectable levels. Staying in close contact with ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...